Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management

Canadian Pharmacists Journal

Volumn 149, Issue 3, 2016, Pages 139-152

  Tisdale, James E ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; AMIODARONE; ARIPIPRAZOLE; AZITHROMYCIN; BORTEZOMIB; CIPROFLOXACIN; CITALOPRAM; CLOMIPRAMINE; DABRAFENIB; DISOPYRAMIDE; DOFETILIDE; ESCITALOPRAM; FLECAINIDE; FLUCONAZOLE; IBUTILIDE; LAPATINIB; LITHIUM; NILOTINIB; PANTOPRAZOLE; PAROXETINE; PROCAINAMIDE; PROPOFOL; QUINIDINE; RISPERIDONE; SERTRALINE; SEVOFLURANE; SOTALOL; UNINDEXED DRUG; VANDETANIB; VENLAFAXINE;

CLINICAL PRACTICE; ELECTROCARDIOGRAM; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; KIDNEY INJURY; PHARMACIST; QT PROLONGATION; REVIEW; RISK ASSESSMENT; TORSADE DES POINTES;

EID: 84964803563     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163516641136     Document Type: Review

References (40)

1. J.LexchinDrug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ2005;172:765-7.
2. J.E.TisdaleVentricular arrhythmias. In:, editors Drug-induced diseases. Prevention, detection and management. 2nd ed.Bethesda (MD): American Society of Health-Systems Pharmacists; 2010. pp 485-515.
3. R.L.WoosleyK.A.Romero. Welcome to CredibleMeds. Available: www.Crediblemeds.org (accessed Nov. 6, 2015).
4. K.E.TrinkleyR.L.PageIIH.Lien. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin2013;29:1719-26.
5. H.C.BazettAn analysis of time relationships of the electrocardiogram. Heart1920;7:353-70.
6. B.J.DrewM.J.AckermanM.Funk.; on behalf of the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing and the American College of Cardiology Foundation. Prevention of torsades de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation2010;121:1047-60.
7. F.DessertenneLa tachycardie ventriculaire à deux foyers opposes variables. Arch Mal Coeur Vaiss1966;59:263-72.
8. I.GoldenbergW.ZarebaA.J.MossThe long QT syndrome. Curr Probl Cardiol2008;33:629-94.
9. D.MozaffarianE.J.BenjaminA.S.Go.; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation2015;131:e29-e322.
10. A.J.MossP.J.SchwartzR.S.Crampton. The long QT syndrome: prospective longitudinal study of 328 families. Circulation1991;84:1136-44.
11. N.D.SharmaH.S.RosmanI.D.Padhi. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol1998;81:238-40.
12. C.M.PrattS.N.SinghH.R.Al-Khalidi. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol2004;43:1211-1216.
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville (MD): US Department of Health and Human Services; 2005.
14. B.DarpöSpectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl2001;3(suppl K):K70-K80.
15. J.E.TisdaleH.A.WroblewskiB.R.Overholser. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT-interval prolonging drugs. Drug Saf2012;35:459-70.
16. D.PickhamE.HelfenbeinJ.A.Shinn. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) study. Crit Care Med2012;40:394-9.
17. RxList. Top 200 drugs list. Available: www.rxlist.com/script/main/hp.asp (accessed Sept. 22, 2015).
18. L.H.CurtisT.ØstbyeV.Sendersky. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med2003;114:135-41.
19. D.PickhamE.HelfenbeinJ.A.Shinn. How many patients need QT interval monitoring in critical care units? Preliminary report of the QT in Practice study. J Electrocardiol2010;43:572-76.
20. D.ZeltserD.JustoA.Halkin. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine2003;82:282-90.
21. Y.ZhangP.OuyangW.S.Post. Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol2011;174:403-11.
22. M.R.CarnethonM.S.AnthonyW.E.Cascio. A prospective evaluation of the risk of QT prolongation with hormone replacement therapy: the atherosclerosis risk in communities study. Ann Epidemiol2003;13:530-6.
23. C.M.PrattH.R.Al-KhalidiJ.M.Brum. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol2006;48:471-7.
24. D.ShafferS.SingerJ.Korvick. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis2002;35:197-200.
25. B.CharbitS.Christin-MaîtreJ.L.Démolis. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol2009;103:887-90.
26. A.H.KadishP.GreenlandM.C.Limacher. Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvas Electrocardiol2004;9:366-74.
27. K.A.EllenbogenB.S.StamblerM.A.Wood. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol1996;28:130-6.
28. B.S.StamblerM.A.WoodK.A.Ellenbogen. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation1996;94:1613-21.
29. S.SinghR.G.ZobleL.Yellen. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. The Symptomatic Atrial Fibrillation Investigative research on Dofetilide (SAFIRE-D) study. Circulation2000;102:2385-90.
30. C.Torp-PedersenM.MollerP.E.Bloch-Thomsen. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med1999;341:857-65.
31. P.YangH.KankiT.Yang. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation2002;105:1943-8.
32. J.E.TisdaleH.A.JaynesJ.R.Kingery. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes2013;6:479-87.
33. J.E.TisdaleH.A.JaynesJ.R.Kingery. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes2014;7:381-90.
34. M.J.KrantzJ.MartinB.Stimmel. QTc interval screening in methadone treatment. Ann Intern Med2009;150:387-95.
35. R.W.NeumarC.W.OttoM.S.Link. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation2010;122(suppl 3):S729-67.
36. M.S.LinkL.C.BerkowP.J.Kudenchuk. Part 7: adult advanced cardiovascular life support. 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation2015;132(suppl 2):S444-S464.
37. M.ManzD.PfeifferW.Jung. Intravenous treatment with magnesium in recurrent persistent ventricular tachycardia. New Trends Arrhythmias1991;7:437-42.
38. D.TzivoniS.BanaiC.Schuger. Treatment of torsade de pointes with magnesium sulfate. Circulation1988;77:392-7.
39. S.N.SinghA.LazinA.Cohen. Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy. Am Heart J1991;121:601-2.
40. S.TangC.Y.LoW.K.Lo. Sotalol-induced torsade de pointes in a CAPD patient—successful treatment with intermittent peritoneal dialysis (letter). Perit Dial Int1997;17:207-8.